KARYOPHARM THERAPEUTICS INC.
85 WELLS AVENUE, SECOND FLOOR
NEWTON, MA 02459
April 22, 2019
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: | Karyopharm Therapeutics Inc. |
Post-Effective Amendment No. 2 to FormS-3 Registration Statement |
FileNo. 333-226038 |
Request for Acceleration |
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Karyopharm Therapeutics Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Post-Effective Amendment No. 2 to FormS-3 Registration Statement (FileNo. 333-226038), so that it may become effective at 4:00 p.m. Eastern time on April 24, 2019, or as soon thereafter as practicable.
Very truly yours,
Karyopharm Therapeutics Inc. | ||
By: | /s/ Christopher B. Primiano | |
Name: Title: | Christopher B. Primiano Executive Vice President, Chief Business Officer, General Counsel and Secretary |